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A B S T R A C T
Despite being fundamental to all treatment decisions, the breakpoints that deﬁne susceptibility and
resistance to conventional anti-tuberculosis (TB) drugs were traditionally deﬁned based on expert
opinion as opposed to modern microbiological principles. As a result, the breakpoints for several key
drugs (i.e. amikacin, levoﬂoxacin, and moxiﬂoxacin) were too high, resulting in the systematic
misclassiﬁcation of a proportion of resistant strains as susceptible. Moreover, a recent systematic review
of clinical outcome data prompted the World Health Organization (WHO) to make signiﬁcant changes to
its treatment guidelines. For example, capreomycin and kanamycin are no longer recommended for TB
treatment because their use correlates with worse clinical outcomes. This history notwithstanding,
robust breakpoints still do not exist for bedaquiline and delamanid six years after their approval. This was
compounded by the fact that access to both agents for drug-susceptibility testing had initially been
restricted. It is incumbent upon the European Medicines Agency, the United States Food and Drug
Administration, and WHO to ensure that drug developers generate the necessary data to set breakpoints
as a prerequisite for the approval of new agents.
© 2019 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Drug-resistant tuberculosis (TB) is estimated to account for a
quarter of annual deaths attributable to antimicrobial resistance
(Review on Antimicrobial Resistance, 2016). Even if all patients
diagnosed with rifampicin resistant or multidrug resistant (MDR)
TB had received comprehensive drug-susceptibility testing (DST)
and had had access to individualised treatment, a proportion
would have received suboptimal regimens due to ﬂawed DST
results (WHO, 2018a). Furthermore, drugs with likely limited
beneﬁts (capreomycin and kanamycin) were widely used in
accordance with World Health Organization (WHO) recommen-
dations (WHO, 2018b).
The most fundamental reason for incorrect DST results is when
the breakpoints that deﬁne phenotypic resistance are not sound,
which are, in turn, used to deﬁne resistance on the genotypic level
(Heyckendorf et al., 2018). In a landmark opinion piece from 2012,
Ängeby et al. pointed out that, unlike most major bacterial
pathogens, breakpoints to anti-TB drugs were traditionally set
based on expert opinion rather than modern microbiological
principles. In addition, neither the Clinical and Laboratory
Standard Institute nor WHO had documented the evidence used
to set or revise breakpoints comprehensively (Ängeby et al., 2012).
Yet, it was not until the publication of a systematic review of
minimum inhibitory concentration (MIC) and sequencing data for
second-line drugs commissioned by WHO that the extent of the
problem became apparent (WHO, 2018c). Speciﬁcally, the break-
points for several key anti-TB drugs (i.e. amikacin, levoﬂoxacin, and
moxiﬂoxacin) were found to be too high, which meant that a
proportion of resistant strains had been systematically misclassi-
ﬁed as susceptible in routine laboratory practise (WHO, 2018c). In
addition, WHO drug surveillance surveys underestimated the
prevalence of resistance to these drugs, which could be partly
compensated for by taking genotypic information into account
(Zignol et al., 2016, 2018). In this context, it is important to
appreciate that the majority of critical concentrations (CCs), which
were redeﬁned to correspond to epidemiological cut-offs (ECOFFs),
would have had to be withdrawn if WHO had followed the
guidelines by the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) that apply to all other major bacterial
pathogens (EUCAST, 2017). Instead, WHO rightly opted for a
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pragmatic approach by proposing or maintaining CCs despite
limited or poor-quality MIC data because otherwise no phenotypic
DST would have been possible for several key drugs. Only where
the evidence was very poor, were CCs withdrawn (e.g. for D-
cycloserine on Löwenstein-Jensen medium (WHO, 2018c)). In
effect, WHO made the best out of a limited evidence base that was
the result of decades of limited investment and research in this
area.
The most effective approach to avoid this issue in the future
would be for strict regulators such as EUCAST, which sets clinical
breakpoints (CBs) on behalf of the European Medicines Agency
(EMA), to make the determination of the ECOFF and an
accompanying quality control range/target requirements for the
initial approval of an agent (Schön et al., 2019). In fact, EUCAST is
currently taking steps towards this goal by selecting a non-
commercial reference MIC method, for which it will set CBs and
against which commercial or other non-commercial methods can
be calibrated, as is the case for other bacteria (Schön, personal
communication).
This would ensure that MICs from the different phases of
clinical trials are directly comparable, which is not always the case
currently. Moreover, this would, by deﬁnition, avoid the problems
that occurred when EUCAST ﬁrst set CBs for bedaquiline and
delamanid. Because EUCAST did not specify to which media its
provisional bedaquiline CB applied, it effectively deﬁned resistance
inconsistently because the CB of 0.25 mg/L likely corresponds to
the ECOFF on 7H11 but is two dilutions below the ECOFF in the
Mycobacteria Growth Indicator Tube 960 (MGIT) system (EUCAST,
2015, 2018). As a result, Mycobacterium tuberculosis appeared
intrinsically resistant on the latter but not the former medium
(WHO, 2018c). This has recently been rectiﬁed by specifying that
the CB applies to 7H10 and 7H11 only. Unfortunately, EUCAST has
not yet clariﬁed for which medium its delamanid CB is valid,
despite clear evidence of systematic differences between media for
delamanid (EUCAST, 2019; WHO, 2018c). In addition, EUCAST has
not yet summarised the MIC, pharmacokinetic/pharmacodynamic
(PK/PD), and clinical data underpinning these CBs as it does for
other bacteria. By contrast, WHO stratiﬁed the MIC data for
bedaquiline and delamanid by medium and, consequently, set
appropriate interim CCs for 7H11 and MGIT, pending additional
data from more laboratories to deﬁne robust ECOFFs according to
EUCAST criteria (EUCAST, 2017; WHO, 2018c).
The difﬁculties with setting sound CBs are exacerbated by the
fact that measuring clinical outcomes for TB is inherently
challenging as TB is treated with multiple drugs over prolonged
periods (Ängeby et al., 2012). Furthermore, the PK/PD drivers for
efﬁcacy of several drugs are poorly understood, which means that
drug dosing may not be optimal (Gumbo et al., 2015). Nevertheless,
these data are crucial for setting one or two clinical CBs per drug, as
deﬁned by EUCAST (Kahlmeter, 2015). Indeed, the ECOFF merely
represents the upper end of the distribution of phenotypically wild
type strains and is therefore the lowest possible CB, but not
automatically the CB (i.e. it is possible to deﬁne ECOFFs even for
compounds that have no clinical beneﬁt). Two recent decisions
illustrate the importance of evaluating clinical data. First, a recent
meta-analysis commissioned by WHO showed that the use of
capreomycin and kanamycin correlate with unfavourable treat-
ment outcomes, which, assuming that biases were adequately
controlled for, suggests that both drugs have no or only limited
clinical beneﬁts, although kanamycin likely plays a more impor-
tant role in the shorter MDR-TB regimen (Collaborative Group for
the Meta-Analysis of Individual Patient Data in MDR-TB treatment
et al., 2018). Based on the data from that review, the updated WHO
treatment guidelines no longer recommend capreomycin and
kanamycin for treatment of MDR-TB (WHO, 2018b). Second,
clinical evidence is even more important when deﬁning CBs above
the ECOFF. In 2014, WHO decided that even the standard dose of
moxiﬂoxacin (i.e. 400 mg daily) was sufﬁcient to treat strains with
MICs that were up to 8 times higher than what we now know
corresponds to the ECOFF for this drug (i.e. 2 mg/L vs. 0.25 mg/L in
MGIT). No evidence was provided for this decision (WHO, 2014).
This change was reversed in 2018, when WHO extrapolated
outcome data for low- and high-dose gatiﬂoxacin to moxiﬂoxacin
to restrict the use of standard dose moxiﬂoxacin to strains with
MICs equal to or below the ECOFF (WHO, 2018c).
Unlike for antiviral drugs, the elucidation of resistance
mechanisms for bacteria is not currently mandated as part of
the approval process (Köser et al., 2015). However, thanks to the
advances in next-generation sequencing it is now feasible to
sequence the genomes of hundreds of mutants selected under
different in vitro and in vivo conditions to elucidate most, if not all,
resistance genes to a drug. For example, a recent study found that
cofC (Rv2983) not only confers cross-resistance to nitroimidazoles
but also renders mutants hypersusceptible to the decontamination
agent malachite green (Rifat et al., 2018). Consequently, these
mutants may evade detection on solid media that contain this
agent. Had this been known earlier, regulators may have required
for this to be formally labelled and may have recommended for
media without this compound to be used to monitor patients
treated with delamanid.
The resistance mechanisms to bedaquiline also have important
practical implications. At the time of the approval of bedaquiline in
2012, only mutations in atpE, which encodes a subunit of the ATP
synthase and represents the target of bedaquiline, were known. It
took another two years for mutations in the transcriptional efﬂux
pump repressor MmpR (Rv0678) to be shown to confer cross-
resistance to bedaquiline and clofazimine and a further two years
for pepQ to emerge as another mechanism for cross-resistance
(Almeida et al., 2016; Köser et al., 2015). Again, EMA or the United
States Food and Drug Administration (FDA) might have included
information about this cross-resistance in the label of bedaquiline
if these data had been available at the time of its approval (Köser
et al., 2015). Moreover, the discovery of mmpR and pepQ were
important since, unlike aptE, mutations in these genes confer only
modest MIC increases, which means that their resulting MIC
distributions are divided by the existing WHO CCs for bedaquiline
(WHO, 2018c). Therefore, the reproducibility of phenotypic DST for
these mechanisms is likely poor (i.e. there is a high likelihood that
resistant strains are misclassiﬁed as susceptible because of the
variation in testing alone) (WHO, 2018c). Unfortunately, interpret-
ing the genotypic information for both of these non-essential
resistance genes is also difﬁcult, as the spectrum of resistance
mutations is large (WHO, 2018c). This complicates individual
patient treatment as well as efforts to study clinical outcome data
for these mechanisms as part of the ongoing clinical trials.
The shortcomings in the regulatory process were compounded
by the fact that, until recently, it had been challenging to obtain
pure bedaquiline and delamanid. For bedaquiline, applications
have to be made to the National Institute of Health in the United
States. Until 2018 the substance was released for research use only
and is still restricted to 20 mg and 40 mg per year for national and
WHO supra-national reference laboratories, respectively. Com-
mercial entities and regional laboratories did not have access to the
pure compound. This meant that only a small proportion of the
24,659 patients who had been treated with bedaquiline under
programmatic conditions in 40 high TB and MDR-TB burden
countries received DST results (DR-TB Scale-Up Treatment Action
Team). Pure delamanid was initially only available for research use
and upon signing a study speciﬁc memorandum of understanding.
Because of this, the Swiss national reference laboratory had to
resort to using crushed bedaquiline and delamanid for DST when
investigating acquired bedaquiline and delamanid resistance in a
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patient with extensively drug resistant (XDR) TB (Bloemberg et al.,
2015; Keller et al., 2015). This lack of quality-controlled routine DST
capacity is concerning as there is some pre-existing resistance to
both bedaquiline and delamanid (i.e. natural resistance that is not
due to selection by either drug or clofazimine (WHO, 2018c)).
Moreover, there is increasing evidence for the rapid selection of
mmpR mutations, particularly in the context of weak background
regimens (Bloemberg et al., 2015; Zimenkov et al., 2017).
The recent decision by WHO to reclassify bedaquiline as a group
A drug means that bedaquiline should be used for all MDR-TB
patients who are treated with the longer MDR-TB regimens (WHO,
2018b). In 2017, 139,114 patients were started on MDR-TB
treatment (out of an estimated 558,000 new cases) (WHO,
2018a). If all patients currently diagnosed with MDR-TB were
initiated on bedaquiline containing regimens, the number of
patients receiving bedaquiline would quintuple. Although delam-
anid roll-out has lagged behind, several cohorts of XDR-TB patients
have received the drug. Consequently, global DST capacity needs to
increase rapidly to provide universal DST for all patients receiving
the new drugs (Cox et al., 2018). Speciﬁcally, baseline and follow-
up isolates need to undergo DST. This will reduce the likelihood of
transmitted resistance and will minimise acquired resistance to
other group A drugs used in a regimen, such as linezolid.
In summary, despite the consensus that antibiotic resistance
represents a key driver for poor treatment outcomes, the standards
to deﬁne resistance that apply to all other major bacterial
pathogens have not been followed for traditional anti-TB drugs
(Ängeby et al., 2012; Kahlmeter, 2015). By commissioning two
landmark systematic reviews, WHO has taken important steps to
rectify this issue, but a more concerted effort is needed by the
wider TB ﬁeld and funders. Six years after the approval of
bedaquiline and delamanid, data to deﬁne robust CBs based on
EUCAST criteria are still lacking. We call on the manufacturers of
both drugs to support activities to rectify this shortcoming.
Moreover, it is incumbent upon EMA and FDA to ensure that
history does not repeat itself when they approve novel anti-TB
agents. In addition, because WHO effectively controls the market
size for novel drugs, it should adopt a more muscular approach to
ensure that pure, quality-controlled compounds are available
immediately to all laboratories wishing to implement phenotypic
DST. Furthermore, standard operating procedures for DST, a
standardised validation protocol, and a set of resistant reference
strains need to be made available at the time of approval of an
agent, as opposed to with long delays (WHO, 2018d). Finally,
external quality assurance schemes are urgently needed to ensure
high-quality DST results.
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